Regional therapy for recurrent Metastatic Melanoma confined to the extremity: Hyperthermic isolated limb perfusion vs. isolated limb infusion

Cancers

Volumn 2, Issue 1, 2010, Pages 43-50

  Reintgen, Michael ^a   Reintgen, Christian ^a   Nobo, Christopher ^a   Giuliano, Rosemary ^b   Shivers, Steven ^c   Reintgen, Douglas ^a  

^a Lakeland Regional Cancer Center   (United States)

^b Department of Surgery   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Extremity; Hyperthermia; Isolated limb perfusion; Metastatic melanoma

Indexed keywords

BCG VACCINE; MELPHALAN;

ADULT; ARM DISEASE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTHERMIC ISOLATED LIMB PERFUSION; INTERMETHOD COMPARISON; ISOLATED LIMB INFUSION; LEG DISEASE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; MICROMETASTASIS; MULTICENTER STUDY; RECURRENT CANCER; SENTINEL LYMPH NODE; SURGICAL TECHNIQUE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79952152958     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers20100043     Document Type: Article

References (12)

1. Creech, O.; Kremetz, E.T.; Ryan, R.F.; Winblad, J.N. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann. Surg. 1958, 184, 616-632.
2. Kroon, H.M.; Moncrieff, M.; Kam, P.; Thompson, J. Outcomes following isolated limb infusion for melanoma. A 14 year experience. Ann. Surg. Oncol. 2008, 15, 3003-3013.
3. Tyler, D. Regional Therapeutic strategies in melanoma: not just local disease control, but an opportunity to develop novel therapeutic strategies with potential implications for systemic therapy. Ann. Surg. Oncol. 2008, 15, 2987-2990.
4. Reintgen, D.S.; Cruse, C.W.; Wells, K.; Saba, H.; Slingluff, C. Isolated limb perfusion for recurrent melanoma of the extremity. Ann. Plastic. Surg. 1992, 28, 50-54.
5. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatments (WHO Offset Publication No. 48); World Health Organization: Geneva, Switzerland, 1979.
6. Beasley, G.M.; Caudle, A.; Petersen, R.P.; McMahon, N.S.; Padussis, J.; Mosca, P.J.; Zager, J.S.; Hochwald, S.N.; Grobmyer, S.R.; Delman, K.A.; Andtbacka, R.H.; Noyes, R.D.; Kane, J.M.; Seigler, H.; Pruitt, S.K.; Ross, M.I.; Tyler, D.S. A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the United States. J. Am. Coll. Surg. 2008, 208, 706-715.
7. Brady, M.S.; Brown, K.; Patel, A.; Fisher, C.; Marx, W. A phase ii trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann. Surg. Oncol. 2006, 13, 1123-1129.
8. Beasley, G.M.; Petersen, R.P.; Yoo, J.; McMahon, N.; Aloia, T.; Petros, W.; Sanders, G.; Cheng, T.Y.; Pruitt, S.K.; Seigler, H.; Tyler, D.S. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann. Surg. Oncol. 2008, 15, 2195-2205.
9. Cornett, W.R.; McCall, L.M.; Petersen, R.P.; Ross, M.I.; Briele, H.A.; Noyes, R.D.; Sussman, J.J.; Kraybill, W.G.; Kane, J.M., III; Alexander, H.R.; Lee, J.E.; Mansfield, P.F.; Pingpank, J.F.; Winchester, D.J.; White, R.L., Jr; Chadaram, V.; Herndon, J.E., II; Fraker, D.L.; Tyler, D.S. Prospective randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J. Clin. Oncol. 2006, 24, 4196-4201.
10. Grunhagen, D.J.; van Etten, B.; Brunstein, F.; Graveland, W.J.; van Geel, A.N.; de Wilt, J.H.W.; Eggermont, A.M.M. Efficacy of repeat isolated limb perfusion with tumor necrosis factor alpha and melphlan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann. Surg. Oncol. 2005, 12, 609-615.
11. Taber, S.W.; Polk, H. Mortality, major amputation rates and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann. Surg. Oncol. 1997, 4, 440-445.
12. Vrouenraets, B.C.; Klaase, J.M.; Kroon, B.B.; van Geel, B.N.; Eggermont, A.; Franklin, H.R. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. Arch. Surg. 1995, 130, 43-47.